Stocklytics Platform
Asset logo for symbol KYMR
Kymera Therapeutics
KYMR54
$42.30arrow_drop_up8.46%$3.30
Asset logo for symbol KYMR
KYMR54

$42.30

arrow_drop_up8.46%

Performance History

Chart placeholder
Key Stats
Open$39.43
Prev. Close$39.00
EPS-2.51
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.39B
PE Ratio-
LOWHIGH
Day Range39.19
42.72
52 Week Range9.60
45.31
Ratios
P/B Ratio5.51
Revenue$78.59M
Operating M. %-514.30%
Earnings$0.00
Earnings Growth %5.07%
EBITDA Margin %-216.90%
ROE %-26.35%
EPS-2.51

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$948.40
Perf. (24h)
arrow_drop_up1.52%$14.26
Market Cap$841.10B
Price$511.53
Perf. (24h)
arrow_drop_up1.42%$7.17
Market Cap$464.20B
Price$149.88
Perf. (24h)
arrow_drop_up0.12%$0.18
Market Cap$360.27B
Price$127.76
Perf. (24h)
arrow_drop_down0.93%-$1.21
Market Cap$326.65B

About Kymera Therapeutics (KYMR)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Headquarters
Watertown
Employees
181
Exchange
NASDAQ
add Kymera Therapeutics to watchlist

Keep an eye on Kymera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Kymera Therapeutics's (KYMR) price per share?

The current price per share for Kymera Therapeutics (KYMR) is $42.3. The stock has seen a price change of $3.3 recently, indicating a 8.46% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Kymera Therapeutics (KYMR)?

For Kymera Therapeutics (KYMR), the 52-week high is $45.31, which is 7.12% from the current price. The 52-week low is $9.6, the current price is 340.62% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Kymera Therapeutics (KYMR) a growth stock?

Kymera Therapeutics (KYMR) has shown an average price growth of 0.41% over the past three years. It has received a score of 46 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Kymera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Kymera Therapeutics (KYMR) stock price performance year to date (YTD)?

As of the latest data, Kymera Therapeutics (KYMR) has a year-to-date price change of 66.86%. Over the past month, the stock has experienced a price change of 21.31%. Over the last three months, the change has been 23%. Over the past six months, the figure is 49.95%.

help
Is Kymera Therapeutics (KYMR) a profitable company?

Kymera Therapeutics (KYMR) has a net income of -$146.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -514.3% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $78.59M, with a revenue growth rate of 67.84%, providing insight into the company's sales performance and growth. The gross profit is $75.03M. Operating income is noted at -$165.53M. Furthermore, the EBITDA is -$170.46M.

help
What is the market capitalization of Kymera Therapeutics (KYMR)?

Kymera Therapeutics (KYMR) has a market capitalization of $2.39B. The average daily trading volume is 928.58K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level